"A leading international drug manufacturer has been engaged with to bulk produce commercial-quality Brilacidin, aimed at lowering patient drug cost and anticipating future drug needs in preparation for expedient market introduction. This critical step also proactively facilitates future patient and insurance reimbursement adoption through favorable cost savings ... "
This is (at least) as important as the CDA news.
IPIX can elect to emphasize foreign markets first, the USA later. Such a course could lead quickly to revenue and even, that favorite of all investors, earnings per share.
News 
Market Data 
Discover 
AI
